Human Mesenchymal Stem Cells - Amnion

Drug testing, regenerative medicine, disease research

Amnion-derived Human Mesenchymal Stem Cells (hMSCs) possess several distinctive features that differentiate them from MSCs derived from other tissues, such as bone marrow, adipose tissue, and umbilical cord. One of the most significant distinctions is their origin from the amnion, a membrane of the placenta, which endows them with unique biological properties. Unlike MSCs from adult tissues, amnion hMSCs are more primitive and exhibit higher proliferative capacity, allowing for extended expansion in culture without significant loss of differentiation potential or stemness. This high proliferative capacity is particularly advantageous for applications requiring large cell quantities, such as tissue engineering and regenerative medicine.

Another key difference lies in the immunomodulatory properties of amnion hMSCs. These cells demonstrate enhanced immunosuppressive abilities compared to MSCs from other sources, making them highly effective in modulating immune responses. This property is especially useful in research focused on inflammatory diseases, autoimmune conditions, and graft-versus-host disease (GVHD). Amnion hMSCs also secrete a distinct profile of bioactive molecules, including anti-inflammatory cytokines and growth factors, which contribute to their superior capacity for promoting tissue repair and reducing inflammation in various in vitro models.

Additionally, amnion hMSCs are known for their lower immunogenicity compared to MSCs derived from other tissues. This reduced potential to elicit an immune response makes them particularly suitable for allogeneic applications and co-culture systems, where interactions between different cell types are studied without the complication of immune rejection. Furthermore, amnion hMSCs are ethically sourced from the placental tissue of healthy donors, eliminating ethical concerns associated with MSCs derived from more invasive procedures, such as bone marrow aspiration. Collectively, these attributes make amnion hMSCs a unique and versatile tool for a wide range of biomedical research applications.

Adherent

Please inquire

Caucasian

1

Alpha MEM, w: 2.0 mM stable Glutamine, w/o: Ribonucleosides, w/o: Deoxyribonucleosides, w: 1.0 mM Sodium pyruvate, w: 2.2g/L NaHCO3

Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.

CM-1 (Cytion catalog number 800100)

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.
To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

Our cells are provided for in vitro laboratory research purposes exclusively and are not intended for clinical or diagnostic use, nor are they to be administered to humans or used for veterinary purposes. Users must adhere to all applicable guidelines and regulations for the handling and use of these cells in a research setting.

1 to 3 x 10^3 cells/cm^2

Trypsin-EDTA